Galapagos Shelves Ulcerative Colitis Program After PhII Failure
This article was originally published in Scrip
Danish firm Galapagos NV has dropped development of its GLPG1205 in ulcerative colitis after it failed a Phase IIa trial. The G-protein coupled receptor 84-targeting small molecule was not shown with statistical significance to be more efficacious than placebo in the company's ORIGIN study. Details of the trial results will be published later this year, the firm said.
You may also be interested in...
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.
Merck & Co is gradually catching up with Roche in PD-1/L1 first-line triple-negative breast cancer treatment, but its presentation at ASCO on Keynote-355 includes mixed PFS results. Overall survival data will be key to Keytruda’s competitiveness.
INFOGRAPHIC: A snapshot of the compensation packages granted to the chiefs of the world’s biggest pharma companies, along with key performance stats for the businesses they lead.